Clinical Trials Browser

Phase 2/3 × luspatercept × 90 days × Clear all

NCT07539779 2026-04-20

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

Phase 2/3 Not yet recruiting

MyeloidOther hematologic neoplasm

Hematologic Neoplasms, Primary Myelofibrosis